新型抗凝药物研究进展  

Advances in the research of new anticoagulants

作　　者：汪燕[1] 

机构地区：[1]卫生部中日友好医院心血管病中心,北京100029

出　　处：《中国新药杂志》2011年第6期514-517,共4页Chinese Journal of New Drugs

摘　　要：抗凝药物被广泛用于血栓栓塞性疾病的预防和治疗。传统抗凝药如肝素、低分子肝素、华法林由于存在某些缺点,临床应用受到限制。理想的抗凝药物应具备高效、安全、口服给药等特征。针对凝血过程中的关键环节成功研发了诸多新型抗凝药物,以Xa因子抑制剂利伐沙班和阿哌沙班以及直接凝血酶抑制剂达比加琼脂为代表的新型抗凝药物在新近的临床研究中被证明不劣于传统抗凝药,文中对这些新型抗凝药的研究进展进行综述。Anticoagulants have been widely used in the prevention and treatment of thromboembolic disorders.However,these traditional drugs,such as unfractionated heparin,low molecular weight heparins and warfarin,have some drawbacks,which limit their use in the clinical setting.The ＂ideal＂ anticoagulant should have some potential benefits including high efficacy,safety and could be orally administered.A number of new anticoagulants have been successfully developed according to the key steps in the coagulation cascade.Among these new anticoagulants,factor Xa inhibitors and direct thrombin inhibitors such as rivaroxaban,apixaban and dabigatran etexilate have been proved to be not inferior to the traditional drugs according to the current clinical studies.The good prospect of anticoagulant therapy is at hand,and it will take the management of thromboembolic disorders to a new era.

关 键 词：抗凝药物 XA因子抑制剂 凝血酶抑制剂 肝素 

分 类 号：R973.2[医药卫生—药品]